亚辉龙中枢神经疾病检测领域实现重大突破

Core Viewpoint - Shenzhen Yahui Long Biotechnology Co., Ltd. has achieved a significant breakthrough in the detection of central nervous system diseases with the approval of its soluble CD146 detection kit (chemiluminescence method) by the Guangdong Provincial Drug Administration, marking a total of 173 domestic chemiluminescent reagent products [1] Group 1: Clinical Significance - Soluble CD146 (sCD146) levels are significantly elevated in cerebrospinal fluid (CSF) of patients with central nervous system autoimmune inflammatory demyelinating diseases, such as multiple sclerosis (MS) and neuromyelitis optica, providing a potential diagnostic marker [2][3] - Traditional laboratory indicators for these diseases have limitations, including complex procedures and long detection cycles, while Yahui Long's innovative chemiluminescence method simplifies operations and enhances sensitivity and specificity [2][3] Group 2: Diagnostic Potential - CSF sCD146 is a sensitive marker for neuroinflammation and blood-brain barrier damage, with a ROC curve area of 0.9962, indicating its effectiveness in monitoring neuroinflammatory diseases [3] - In active MS patients, CSF sCD146 levels are significantly higher compared to non-demyelinating disease controls and non-active MS patients, suggesting its potential as a new biomarker for monitoring MS activity [4] Group 3: Collaborative Innovation - The soluble CD146 detection kit is a globally pioneering technology developed in collaboration with Professor Yan Xiyun, a renowned academician and expert in nanobiology, enhancing China's international standing in the diagnostic field for these diseases [5] - Yahui Long is conducting multi-center studies with Xuanwu Hospital to establish new diagnostic technologies and solutions based on sCD146, while also exploring its clinical value in obstetrics, autoimmune diseases, cardiovascular issues, and oncology [5][6]